ZA201601443B - Administration of kynurenine depleting enzymes for tumor therapy - Google Patents
Administration of kynurenine depleting enzymes for tumor therapyInfo
- Publication number
- ZA201601443B ZA201601443B ZA2016/01443A ZA201601443A ZA201601443B ZA 201601443 B ZA201601443 B ZA 201601443B ZA 2016/01443 A ZA2016/01443 A ZA 2016/01443A ZA 201601443 A ZA201601443 A ZA 201601443A ZA 201601443 B ZA201601443 B ZA 201601443B
- Authority
- ZA
- South Africa
- Prior art keywords
- administration
- tumor therapy
- depleting enzymes
- kynurenine
- kynurenine depleting
- Prior art date
Links
- YGPSJZOEDVAXAB-UHFFFAOYSA-N kynurenine Chemical compound OC(=O)C(N)CC(=O)C1=CC=CC=C1N YGPSJZOEDVAXAB-UHFFFAOYSA-N 0.000 title 2
- 102000004190 Enzymes Human genes 0.000 title 1
- 108090000790 Enzymes Proteins 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 230000000779 depleting effect Effects 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4244—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y307/00—Hydrolases acting on carbon-carbon bonds (3.7)
- C12Y307/01—Hydrolases acting on carbon-carbon bonds (3.7) in ketonic substances (3.7.1)
- C12Y307/01003—Kynureninase (3.7.1.3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Hematology (AREA)
- Developmental Biology & Embryology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361872132P | 2013-08-30 | 2013-08-30 | |
| US201461986366P | 2014-04-30 | 2014-04-30 | |
| PCT/US2014/053437 WO2015031771A2 (en) | 2013-08-30 | 2014-08-29 | Administration of kynurenine depleting enzymes for tumor therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201601443B true ZA201601443B (en) | 2019-08-28 |
Family
ID=52583559
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2016/01443A ZA201601443B (en) | 2013-08-30 | 2016-03-02 | Administration of kynurenine depleting enzymes for tumor therapy |
Country Status (12)
| Country | Link |
|---|---|
| US (5) | US9808486B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3492094A1 (cg-RX-API-DMAC7.html) |
| JP (4) | JP6307163B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR102271498B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN113957061A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2014312119B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112016004095A2 (cg-RX-API-DMAC7.html) |
| CA (2) | CA3173052A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2707711T3 (cg-RX-API-DMAC7.html) |
| IL (2) | IL244312B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2015031771A2 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA201601443B (cg-RX-API-DMAC7.html) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2776698T3 (es) | 2012-12-20 | 2020-07-31 | Purdue Research Foundation | Células T que expresan un receptor antigénico quimérico como terapia contra el cáncer |
| CA3173052A1 (en) | 2013-08-30 | 2015-03-05 | Board Of Regents, The University Of Texas System | Administration of kynurenine depleting enzymes for tumor therapy |
| ES2987380T3 (es) | 2014-08-29 | 2024-11-14 | Univ Texas | Administración de enzimas de depleción de la quinurenina para la terapia tumoral |
| PL3207130T3 (pl) | 2014-10-14 | 2020-02-28 | Halozyme, Inc. | Kompozycje deaminazy adenozyny 2 (ada2), jej warianty i sposoby ich zastosowania |
| US20180079824A1 (en) * | 2015-03-18 | 2018-03-22 | Baylor College Of Medicine | HER2/ErbB2 Chimeric Antigen Receptor |
| CA3011283A1 (en) | 2016-01-11 | 2017-07-20 | Synlogic Operating Company, Inc. | Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells |
| WO2017151860A1 (en) | 2016-03-02 | 2017-09-08 | Broard Of Regents, The University Of Texas System | Human kynureninase enzyme variants having improved pharmacological properties |
| JP7282521B2 (ja) | 2016-04-08 | 2023-05-29 | パーデュー・リサーチ・ファウンデイション | Ｃａｒ ｔ細胞療法のための方法および組成物 |
| CA3037387A1 (en) | 2016-10-13 | 2018-04-19 | Juno Therapeutics, Inc. | Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators |
| US11649288B2 (en) | 2017-02-07 | 2023-05-16 | Seattle Children's Hospital | Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents |
| WO2018160622A1 (en) | 2017-02-28 | 2018-09-07 | Endocyte, Inc. | Compositions and methods for car t cell therapy |
| WO2019014391A1 (en) | 2017-07-12 | 2019-01-17 | Synlogic Operating Company, Inc. | MICROORGANISMS PROGRAMMED TO PRODUCE IMMUNOMODULATORS AND ANTICANCER THERAPEUTIC AGENTS IN TUMOR CELLS |
| WO2019089740A1 (en) * | 2017-11-03 | 2019-05-09 | Dana-Farber Cancer Institute, Inc. | Biomarkers of clinical response and benefit to immune checkpoint inhibitor therapy |
| CN112292138A (zh) | 2018-01-22 | 2021-01-29 | 西雅图儿童医院（Dba西雅图儿童研究所） | Car t细胞的使用方法 |
| SG11202007426XA (en) | 2018-02-06 | 2020-09-29 | Seattle Childrens Hospital Dba Seattle Childrens Res Inst | Fluorescein-specific cars exhibiting optimal t cell function against fl-ple labelled tumors |
| WO2019165237A1 (en) | 2018-02-23 | 2019-08-29 | Endocyte, Inc. | Sequencing method for car t cell therapy |
| WO2019204269A1 (en) | 2018-04-16 | 2019-10-24 | Board Of Regents, The University Of Texas System | Human kynureninase enzymes and uses thereof |
| CN110412179A (zh) * | 2018-04-26 | 2019-11-05 | 缪荣明 | 一种液相色谱检测颗粒酶a的方法 |
| WO2020120982A2 (en) * | 2018-12-14 | 2020-06-18 | Autolus Limited | Cell |
| AU2020366452A1 (en) * | 2019-10-17 | 2022-05-05 | The Board Of Regents Of The University Of Texas System | Pegylated kynureninase enzymes and uses thereof for the treatment of cancer |
| JPWO2023229024A1 (cg-RX-API-DMAC7.html) * | 2022-05-27 | 2023-11-30 | ||
| WO2024085280A1 (ko) * | 2022-10-20 | 2024-04-25 | 서울대학교 산학협력단 | 신규한 키뉴레니나제 및 이의 용도 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5824311A (en) | 1987-11-30 | 1998-10-20 | Trustees Of The University Of Pennsylvania | Treatment of tumors with monoclonal antibodies against oncogene antigens |
| US4870287A (en) | 1988-03-03 | 1989-09-26 | Loma Linda University Medical Center | Multi-station proton beam therapy system |
| US5329028A (en) | 1992-08-05 | 1994-07-12 | Genentech, Inc. | Carbohydrate-directed cross-linking reagents |
| US5846945A (en) | 1993-02-16 | 1998-12-08 | Onyx Pharmaceuticals, Inc. | Cytopathic viruses for therapy and prophylaxis of neoplasia |
| US5801005A (en) | 1993-03-17 | 1998-09-01 | University Of Washington | Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated |
| GB9506466D0 (en) | 1994-08-26 | 1995-05-17 | Prolifix Ltd | Cell cycle regulated repressor and dna element |
| US5760395A (en) | 1996-04-18 | 1998-06-02 | Universities Research Assoc., Inc. | Method and apparatus for laser-controlled proton beam radiology |
| US5739169A (en) | 1996-05-31 | 1998-04-14 | Procept, Incorporated | Aromatic compounds for inhibiting immune response |
| US6812339B1 (en) * | 2000-09-08 | 2004-11-02 | Applera Corporation | Polymorphisms in known genes associated with human disease, methods of detection and uses thereof |
| US20030194721A1 (en) | 2001-09-19 | 2003-10-16 | Incyte Genomics, Inc. | Genes expressed in treated foam cells |
| US20030215840A1 (en) | 2002-02-01 | 2003-11-20 | Millennium Pharmaceuticals, Inc. | Methods and compositions for treating cardiovascular disease using 1682, 6169, 6193, 7771, 14395, 29002, 33216, 43726, 69292, 26156, 32427, 2402, 7747, 1720, 9151, 60491, 1371, 7077, 33207, 1419, 18036, 16105, 38650, 14245, 58848, 1870, 25856, 32394, 3484, 345, 9252, 9135, 10532, 18610, 8165, 2448, 2445, 64624, 84237, 8912, 2868, 283, 2554, 9464, 17799, 26686, 43848, 32135, 12208, 2914, 51130, 19489, 21833, 2917, 59590, 15992, 2094, 2252, 3474, 9792, 15400, 1452 or 6585 molecules |
| CN1330774C (zh) * | 2002-03-01 | 2007-08-08 | 国家人类基因组南方研究中心 | 犬尿氨酸水解酶多态性及其用途 |
| WO2004093871A1 (en) * | 2003-03-27 | 2004-11-04 | Lankenau Institute For Medical Research | Novel methods for the treatment of cancer |
| US20070207158A1 (en) | 2003-06-17 | 2007-09-06 | Harrison Roger G | Conjugate for the specific targeting of anticancer agents to tumor cells or tumor vasculature and production thereof |
| EP1648512A4 (en) | 2003-07-31 | 2009-01-21 | Immunomedics Inc | ANTI-CD19 ANTIBODIES |
| JP2008237022A (ja) | 2005-06-30 | 2008-10-09 | Osaka Prefecture | 非小細胞肺がんの予防・治療剤および診断薬 |
| CA2663057C (en) | 2006-09-19 | 2015-12-08 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| GB0625310D0 (en) * | 2006-12-19 | 2007-01-24 | Bioalvo | Yeast platform construction and screening methods |
| US8465743B2 (en) | 2009-10-01 | 2013-06-18 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer |
| PT3012268T (pt) | 2010-09-08 | 2018-01-31 | Chemotherapeutisches Forschungsinstitut Georg Speyer Haus | Recetores de antigénio quimérico com uma região de charneira otimizada |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| WO2012099441A2 (ko) | 2011-01-21 | 2012-07-26 | 인제대학교산학협력단 | 트립토판 대사효소 유전자를 발현하는 줄기세포를 함유하는 면역 반응 억제용 조성물 |
| KR20120085209A (ko) * | 2011-01-21 | 2012-07-31 | 인제대학교 산학협력단 | 트립토판 대사효소 유전자를 발현하는 줄기세포를 함유하는 면역 반응 억제용 조성물 |
| WO2013034685A1 (en) * | 2011-09-07 | 2013-03-14 | Deutsches Krebsforschungszentrum | Means and methods for treating and/or preventing natural ahr ligand-dependent cancer |
| RU2644243C2 (ru) | 2011-10-20 | 2018-02-08 | Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез | Химерные антигенные рецепторы к cd22 |
| CA3173052A1 (en) | 2013-08-30 | 2015-03-05 | Board Of Regents, The University Of Texas System | Administration of kynurenine depleting enzymes for tumor therapy |
| ES2987380T3 (es) | 2014-08-29 | 2024-11-14 | Univ Texas | Administración de enzimas de depleción de la quinurenina para la terapia tumoral |
| WO2017151860A1 (en) | 2016-03-02 | 2017-09-08 | Broard Of Regents, The University Of Texas System | Human kynureninase enzyme variants having improved pharmacological properties |
| JP6912171B2 (ja) * | 2016-09-15 | 2021-07-28 | 株式会社トプコン | 眼科検査装置 |
| WO2019204269A1 (en) | 2018-04-16 | 2019-10-24 | Board Of Regents, The University Of Texas System | Human kynureninase enzymes and uses thereof |
-
2014
- 2014-08-29 CA CA3173052A patent/CA3173052A1/en active Pending
- 2014-08-29 BR BR112016004095A patent/BR112016004095A2/pt not_active Application Discontinuation
- 2014-08-29 WO PCT/US2014/053437 patent/WO2015031771A2/en not_active Ceased
- 2014-08-29 EP EP18204264.8A patent/EP3492094A1/en active Pending
- 2014-08-29 CN CN202111132607.1A patent/CN113957061A/zh active Pending
- 2014-08-29 US US14/473,040 patent/US9808486B2/en active Active
- 2014-08-29 KR KR1020167008486A patent/KR102271498B1/ko active Active
- 2014-08-29 KR KR1020217019661A patent/KR102442231B1/ko active Active
- 2014-08-29 CA CA2922670A patent/CA2922670C/en active Active
- 2014-08-29 JP JP2016537898A patent/JP6307163B2/ja active Active
- 2014-08-29 AU AU2014312119A patent/AU2014312119B2/en active Active
- 2014-08-29 EP EP14840339.7A patent/EP3038636B1/en active Active
- 2014-08-29 CN CN201480053899.1A patent/CN105722522B/zh active Active
- 2014-08-29 ES ES14840339T patent/ES2707711T3/es active Active
-
2016
- 2016-02-28 IL IL244312A patent/IL244312B/en active IP Right Grant
- 2016-03-02 ZA ZA2016/01443A patent/ZA201601443B/en unknown
- 2016-11-14 US US15/351,060 patent/US20170056449A1/en not_active Abandoned
-
2018
- 2018-03-09 JP JP2018042760A patent/JP7029316B2/ja active Active
-
2019
- 2019-02-19 IL IL264901A patent/IL264901B/en active IP Right Grant
- 2019-04-02 US US16/373,588 patent/US10772913B2/en active Active
-
2020
- 2020-04-16 JP JP2020073212A patent/JP2020111611A/ja not_active Withdrawn
- 2020-08-18 US US16/996,806 patent/US11534463B2/en active Active
-
2022
- 2022-08-23 JP JP2022132161A patent/JP2022159570A/ja active Pending
- 2022-12-13 US US18/065,451 patent/US20240091258A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201601443B (en) | Administration of kynurenine depleting enzymes for tumor therapy | |
| IL287516A (en) | Medicinal uses of empagliflozin | |
| IL241101A0 (en) | Medicinal uses of empagliflozin | |
| IL237138A0 (en) | Methods of administration of pirfenidone therapy | |
| IL241102A0 (en) | Medicinal uses of empagliflozin | |
| IL250833A0 (en) | Administering enzymes to reduce the level of kynurenine in the treatment of tumors | |
| IL236678A0 (en) | Crystallin-alpha inhibitors for the treatment of cataracts | |
| PT2879672T (pt) | Terapia combinada para o tratamento da esclerose múltipla | |
| IL240987A0 (en) | Methods for treating solid tumors in children | |
| PL2981271T3 (pl) | Zastosowania terapeutyczne empagliflozyny | |
| IL234813A0 (en) | Methods for increasing the efficacy of cd37-based therapy | |
| PT3228313T (pt) | Formas de dosagem e utilizações terapêuticas de l-4-cloroquinurenina | |
| HK40067079A (zh) | 用於肿瘤疗法的犬尿氨酸耗竭酶的施用 | |
| EP2996716A4 (en) | Correlates of efficacy relating to tumor vaccines | |
| IL244620A0 (en) | A drug combination including laquinimod for the treatment of multiple sclerosis | |
| HK1225291A1 (en) | Laquinimod combination therapy for treatment of multiple sclerosis | |
| GB201322036D0 (en) | New therapeutic uses of enzyme inhibitors | |
| GB201310488D0 (en) | New therapeutic uses of enzyme inhibitors | |
| AU2013902004A0 (en) | Compositions for Therapy and Methods of Treatment |